{"cluster": 20, "subcluster": 79, "abstract_summ": "On 18 samples with neutralizing activity, 17 were positive by Abbott ARCHITECT SARS-CoV-2 IgG. CONCLUSIONS: In our study, Abbott ARCHITECT SARS-CoV-2 IgG assay showed a satisfactory performance, with a very high specificity.Focusing on IgG and total antibodies, we demonstrate the performance of four automated immunoassays (Abbott Architect\u2122 i2000 (N protein-based)), Roche cobas\u2122 e 411 analyzer (N protein-based, not differentiating between IgA, IgM or IgG antibodies), LIAISON\u00aeXL platform (S1 and S2 protein-based), VIRCLIA\u00ae automation system (S1 and N protein-based) in comparison two ELISA assays (Euroimmun SARS-CoV-2 IgG (S1 protein-based) and Virotech SARS-CoV-2 IgG ELISA (N protein-based)) and an in-house developed plaque reduction neutralization test (PRNT).Results: ELISA detected SARS-CoV-2 IgM or IgG in 34/40 individuals with an RT-PCR-confirmed diagnosis of SARS-CoV-2 infection (sensitivity 85%, 95%CI 70-94%), vs 0/50 pre-pandemic controls (specificity 100% [95%CI 93-100%]).METHODS: Using EDI(TM) Novel Coronavirus COVID-19 Enzyme Linked Immunosorbent Assays (ELISAs), we measured SARS-CoV-2 IgM and IgG antibodies in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n=104) collected at different time points from symptom onset.CONCLUSIONS: This study shows high \u201ctrue\u201d vs. low \u201cfalse\u201d positivity rates for the EDI(TM) SARS-CoV-2 IgM and IgG ELISAs.", "title_summ": "Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2.Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassaysValidation of a commercially available SARS-CoV-2 serological ImmunoassayEvaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasmaBrief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assaysMonitoring antibody response following SARS-CoV-2 infection: Diagnostic efficiency of four automated immunoassaysPerformance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization testValidation of a commercially available SARS-CoV-2 serological immunoassay", "title_abstract_phrases": "On 18 samples with neutralizing activity, 17 were positive by Abbott ARCHITECT SARS-CoV-2 IgG. CONCLUSIONS: In our study, Abbott ARCHITECT SARS-CoV-2 IgG assay showed a satisfactory performance, with a very high specificity.Focusing on IgG and total antibodies, we demonstrate the performance of four automated immunoassays (Abbott Architect\u2122 i2000 (N protein-based)), Roche cobas\u2122 e 411 analyzer (N protein-based, not differentiating between IgA, IgM or IgG antibodies), LIAISON\u00aeXL platform (S1 and S2 protein-based), VIRCLIA\u00ae automation system (S1 and N protein-based) in comparison two ELISA assays (Euroimmun SARS-CoV-2 IgG (S1 protein-based) and Virotech SARS-CoV-2 IgG ELISA (N protein-based)) and an in-house developed plaque reduction neutralization test (PRNT).Results: ELISA detected SARS-CoV-2 IgM or IgG in 34/40 individuals with an RT-PCR-confirmed diagnosis of SARS-CoV-2 infection (sensitivity 85%, 95%CI 70-94%), vs 0/50 pre-pandemic controls (specificity 100% [95%CI 93-100%]).METHODS: Using EDI(TM) Novel Coronavirus COVID-19 Enzyme Linked Immunosorbent Assays (ELISAs), we measured SARS-CoV-2 IgM and IgG antibodies in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n=104) collected at different time points from symptom onset.STUDY DESIGN: Abbott ARCHITECT SARS-CoV-2 IgG immunoassay was compared to an indirect immunofluorescence assay (IFA) on sera from patients with COVID-19 collected at different days after symptoms onset or infected by other human coronaviruses."}